Sanofi sees first fruit of renewed oncology commitment with Sarclisa approval
Sanofi solidifies comeback with first FDA cancer approval in more than a decade
Sarclisa isatuximab will be the first oncology drug Sanofi launches in more than a decade, its approval Monday marking the pharma’s first cancer win after its re-entry into the space. The company’s next step is finding a home for the anti-CD38 mAb in a crowded multiple myeloma market.
FDA approved the Sanofi (Euronext:SAN; NASDAQ:SNY) drug in combination with pomalidomide and dexamethasone (pom-dex) to treat relapsed